NASDAQ:CERS Cerus (CERS) Stock Price, News & Analysis $2.71 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$2.70 0.00 (-0.18%) As of 05/22/2026 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cerus Stock (NASDAQ:CERS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cerus alerts:Sign Up Key Stats Today's Range$2.69▼$2.8150-Day Range$1.69▼$2.7452-Week Range$1.15▼$3.15Volume1.73 million shsAverage Volume3.36 million shsMarket Capitalization$543.00 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingHold Company Overview Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients. The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products. Cerus also offers research tool products that enable academic and industrial laboratories to study pathogen inactivation mechanisms and develop further applications of its technology. These tools support investigators in exploring blood safety challenges and advancing transfusion medicine research. Founded in 1991 and headquartered in Concord, California, Cerus has secured regulatory approvals and clearances in multiple markets, including the United States, Europe, Asia-Pacific, and Latin America. Its products are deployed by blood establishments and hospitals across more than 20 countries, where they contribute to improving patient outcomes and supporting public health initiatives. Cerus continues to advance its pipeline with programs targeting pathogen reduction for red blood cells and novel formulations to address emerging infectious threats. The company is led by a management team with extensive experience in biotechnology, transfusion medicine, and regulatory affairs, positioning it to expand the reach of its technology and drive ongoing innovation in blood safety.AI Generated. May Contain Errors. Read More Cerus Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreCERS MarketRank™: Cerus scored higher than 38% of companies evaluated by MarketBeat, and ranked 673rd out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingHold Consensus RatingCerus has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCerus has a consensus price target of $4.00, representing about 47.6% upside from its current price of $2.71.Amount of Analyst CoverageCerus has only been the subject of 3 research reports in the past 90 days.Read more about Cerus' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cerus are expected to grow in the coming year, from ($0.02) to $0.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cerus is -54.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cerus is -54.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCerus has a P/B Ratio of 7.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cerus' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.82% of the float of Cerus has been sold short.Short Interest Ratio / Days to CoverCerus has a short interest ratio ("days to cover") of 10.51, which indicates bearish sentiment.Change versus previous monthShort interest in Cerus has recently increased by 0.61%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCerus does not currently pay a dividend.Dividend GrowthCerus does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Cerus this week, compared to 3 articles on an average week.Search Interest12 people have searched for CERS on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat Follows2 people have added Cerus to their MarketBeat watchlist in the last 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Cerus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,156,291.00 in company stock.Percentage Held by Insiders5.60% of the stock of Cerus is held by insiders.Percentage Held by Institutions78.37% of the stock of Cerus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cerus' insider trading history. Receive CERS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CERS Stock News HeadlinesCerus Corporation (CERS) Gets Upgraded to Buy Post Q1 by BTIGMay 23 at 9:37 AM | finance.yahoo.comCerus Corporation: Strong Q1 Results Validate The Turnaround ThesisMay 10, 2026 | seekingalpha.comSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500. | Brownstone Research (Ad)Cerus (NASDAQ:CERS) COO Vivek Jayaraman Sells 16,667 SharesMay 6, 2026 | insidertrades.comTop 3 Health Care Stocks That May Collapse This MonthMay 4, 2026 | benzinga.comBTIG upgrades Cerus (CERS)May 2, 2026 | msn.comCerus Corporation Earnings Call Signals Profitable GrowthMay 1, 2026 | tipranks.comCerus Corp (CERS) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...May 1, 2026 | finance.yahoo.comSee More Headlines CERS Stock Analysis - Frequently Asked Questions How have CERS shares performed this year? Cerus' stock was trading at $2.06 at the beginning of the year. Since then, CERS shares have increased by 31.6% and is now trading at $2.71. How were Cerus' earnings last quarter? Cerus Corporation (NASDAQ:CERS) released its earnings results on Thursday, April, 30th. The biotechnology company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.02. The biotechnology company earned $59.89 million during the quarter, compared to analysts' expectations of $55.68 million. Cerus had a negative net margin of 4.41% and a negative trailing twelve-month return on equity of 15.18%. Read the conference call transcript. Who are Cerus' major shareholders? Cerus' top institutional shareholders include Wasatch Advisors LP (2.75%), Sumitomo Mitsui Trust Group Inc. (2.25%), Amova Asset Management Americas Inc. (2.25%) and Senvest Management LLC (2.05%). Insiders that own company stock include William Mariner Greenman, Vivek K Jayaraman, Chrystal Jensen, Kevin Dennis Green, Richard J Benjamin, Carol Moore, Eric Bjerkholt, Daniel N Swisher Jr, Ann Lucena and Hua Shan. View institutional ownership trends. How do I buy shares of Cerus? Shares of CERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cerus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cerus investors own include American Water Works (AWK), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), Voyager Therapeutics (VYGR), AUO (AUOTY) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings4/30/2026Today5/24/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 CERS's financial health is in the Green zone, according to TradeSmith. CERS has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:CERS CIK1020214 Webwww.cerus.com Phone(925) 288-6000Fax925-288-6001Employees290Year Founded1991Price Target and Rating Average Price Target for Cerus$4.00 High Price Target$4.00 Low Price Target$4.00 Potential Upside/Downside+47.6%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$15.63 million Net Margins-4.41% Pretax Margin-4.25% Return on Equity-15.18% Return on Assets-4.38% Debt Debt-to-Equity Ratio0.47 Current Ratio1.63 Quick Ratio1.06 Sales & Book Value Annual Sales$206.13 million Price / Sales2.63 Cash FlowN/A Price / Cash FlowN/A Book Value$0.34 per share Price / Book7.97Miscellaneous Outstanding Shares200,370,000Free Float189,148,000Market Cap$543.00 million OptionableOptionable Beta1.62 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:CERS) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerus Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Cerus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
